337 related articles for article (PubMed ID: 36938325)
21. Structural evolution of SARS-CoV-2 omicron in human receptor recognition.
Zhang W; Shi K; Geng Q; Herbst M; Wang M; Huang L; Bu F; Liu B; Aihara H; Li F
J Virol; 2023 Aug; 97(8):e0082223. PubMed ID: 37578233
[TBL] [Abstract][Full Text] [Related]
22. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
[TBL] [Abstract][Full Text] [Related]
23. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
Sah R; Rais MA; Mohanty A; Chopra H; Chandran D; Bin Emran T; Dhama K
Int J Surg Open; 2023 Jun; 55():100625. PubMed ID: 37255735
[TBL] [Abstract][Full Text] [Related]
24. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
[TBL] [Abstract][Full Text] [Related]
25. Digital PCR Discriminates between SARS-CoV-2 Omicron Variants and Immune Escape Mutations.
Holland SC; Holland LA; Smith MF; Lee MB; Hu JC; Lim ES
Microbiol Spectr; 2023 Aug; 11(4):e0525822. PubMed ID: 37306573
[TBL] [Abstract][Full Text] [Related]
26. Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.
Shah M; Woo HG
Front Mol Biosci; 2023; 10():1236617. PubMed ID: 37828918
[TBL] [Abstract][Full Text] [Related]
27. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.
Yang J; Hong W; Lei H; He C; Lei W; Zhou Y; Zhao T; Alu A; Ma X; Li J; Yang L; Wang Z; Wang W; Lu G; Shen G; Lu S; Wu G; Shi H; Wei X
Signal Transduct Target Ther; 2023 Jun; 8(1):252. PubMed ID: 37336889
[TBL] [Abstract][Full Text] [Related]
28. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
[TBL] [Abstract][Full Text] [Related]
29. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
[TBL] [Abstract][Full Text] [Related]
30. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
[TBL] [Abstract][Full Text] [Related]
31. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
bioRxiv; 2022 Nov; ():. PubMed ID: 36415455
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
[TBL] [Abstract][Full Text] [Related]
33. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
Nat Commun; 2023 Feb; 14(1):824. PubMed ID: 36788246
[TBL] [Abstract][Full Text] [Related]
34. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
[TBL] [Abstract][Full Text] [Related]
35. Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.
Katte RH; Ao Y; Xu W; Han Y; Zhong G; Ghimire D; Florence J; Tucker TA; Lu M
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543757
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890
[TBL] [Abstract][Full Text] [Related]
37. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
Yang X; Wang Y; Liang Z; Cui T; Chen D; Li G; Xu H; Liu S; Zhong N; Huang W; Wang Z
J Med Virol; 2024 Jan; 96(1):e29417. PubMed ID: 38258345
[TBL] [Abstract][Full Text] [Related]
38. Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
Di H; Pusch EA; Jones J; Kovacs NA; Hassell N; Sheth M; Lynn KS; Keller MW; Wilson MM; Keong LM; Cui D; Park SH; Chau R; Lacek KA; Liddell JD; Kirby MK; Yang G; Johnson M; Thor S; Zanders N; Feng C; Surie D; DeCuir J; Lester SN; Atherton L; Hicks H; Tamin A; Harcourt JL; Coughlin MM; Self WH; Rhoads JP; Gibbs KW; Hager DN; Shapiro NI; Exline MC; Lauring AS; Rambo-Martin B; Paden CR; Kondor RJ; Lee JS; Barnes JR; Thornburg NJ; Zhou B; Wentworth DE; Davis CT
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793756
[TBL] [Abstract][Full Text] [Related]
39. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
Xiang T; Wang J; Zheng X
Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
